Navigation Links
Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
Date:3/6/2012

Bethesda, MDA new research discovery by a team of Stanford and European scientists offers hope that people with atherosclerotic disease may one day be able to avoid limb amputation related to ischemia. A new research report appearing online in the FASEB Journal suggests that the delivery of genes for two molecules naturally produced by the body, called "PDGF-BB" and "VEGF" may successfully cause the body to grow new blood vessels that can save ischemic limbs.

"We hope that our findings will ultimately develop into a safe and effective therapy for the many patients, suffering from blocked arteries in the limbs, who are currently not adequately treated by surgery or drugs," said Helen M. Blau, Ph.D., a senior researcher involved in the work and Associate Editor of the FASEB Journal from the Baxter Laboratory for Stem Cell Biology at the Institute for Regenerative Medicine and Stem Cell Biology at Stanford. "This could help avoid the devastating consequences of limb amputations for both patients and their families."

To make this discovery, Blau and colleagues, including Andrea Banfi (now at Basel University), introduced the genes for PDGF-BB and VEGF into the muscles of mice, either independently or together. When high doses of VEGF alone were produced, they caused the growth of vascular tumors. When the two factors were produced in unbalanced amounts, tumor growth also occurred. When VEGF and PDGF were delivered in a fixed ratio relative to one another, however, no tumors occurred, and blood flow was restored to ischemic muscle tissue and damage repaired without any toxic effects. To achieve a "balanced" delivery of PDGF-BB and VEGF, scientists placed both genes in a single gene therapy delivery mechanism, called a "vector."

Although the report shows the feasibility of growing robust and safe new blood vessels that restore blood flow to diseased tissues, Blau points out that "there are multiple challenges to correcting peripheral vasculature disease by using proangiogenic gene therapy strategies. Two important challenges are what to deliver and how to get it to where it can have beneficial effects. Clinical success will require both delivering a gene therapy construct that encodes for effective angiogenic factors and ensuring that the sites of delivery are where the construct can have the greatest clinical benefit."

"This ingenious work, based on the latest techniques of molecular biology, tells us that it is possible to reinvigorate parts of our body that can't get enough blood to keep them going," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "The next question is whether this approach will work in humans and exactly how to deliver the new treatment to places that need it the most."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Stanford scientist to discuss the challenges and opportunities of carbon sequestration at AAAS
2. JoVE partners with Stanford University for Medicine X Conference
3. AGU meeting: Stanford scientists subject rocks to hellish conditions to combat global warming
4. Squid mystery in Mexican waters unraveled by Stanford biologist and a class of students
5. OpenSim open-source software from Stanford accurately models human motion
6. Gene variation predicts rate of age-related decline in mental performance, Stanford study
7. Stanford researchers examine impact of green politics on recent national elections
8. Stanford Precourt Institute and TomKat Center award energy research grants
9. Dual-action protein developed at Stanford better restricts blood vessel formation
10. Stanford engineers redefine how the brain plans movement
11. Global warming could alter the US premium wine industry in 30 years, says Stanford study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2018)... ... July 31, 2018 , ... ACEA Biosciences, is a privately owned biotechnology ... just introduced the xCELLigence RTCA S16, which the ideal entry level model for exploratory ... the S16can be placed in any standard CO2 tissue culture incubator. The user ...
(Date:7/29/2018)... ... 2018 , ... Dr. William Plikerd, an evidence-based energy healer, today announces research ... and to combat inflammation and autoimmune disorders. , The preclinical research assessed biomarkers ... Up to 260% increase overall immunity as seen by ...
(Date:7/26/2018)... ... July 26, 2018 , ... Shirley Holmlund, an evidence-based healer, ... energy healing treated Vitamin D3 on the strength and health of bones. The ... improvement in bone mineralization and over 100% increase in ALP, a bone-specific enzyme. ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... August 08, 2018 , ... ActX introduces GenoACT(sm), ... continually updated by a talented scientific team that includes geneticists, PharmD’s, genetic counselors, ... 1. Information on the medical impact of a patient’s genetic variants , 2. ...
(Date:8/9/2018)... ... August 09, 2018 , ... Rockland Immunochemicals, Inc. announced ... Aggeler, Director of Antibody Development at Bio-Techne, composed a peer-reviewed article using their ... on August 9, 2018 and will be printed in the September 2018 issue ...
(Date:8/1/2018)... ... August 01, 2018 , ... ... the significant impact of a proprietary biofield energy treated supplement that potentially ... assessed biomarkers for systemic and organ-specific inflammation, as well as, immune function ...
(Date:7/27/2018)... ... July 27, 2018 , ... ... of the Biotechnology Innovation Organization (BIO) met with U.S. Environmental Protection Agency ... a Toxic Substances Control Act (TSCA) Inventory Representation and Equivalency Determinations for ...
Breaking Biology Technology: